| Most cancer breakthroughs are measured in charts. This one is visible under a microscope. |
| Time-lapse footage from a recent clinical study shows immune cells attacking and eliminating cancer cells. |
| These are Natural Killer (NK) cells, the part of the immune system tasked with identifying and destroying abnormal cells before tumors spread. |
| But in advanced cancers, they can become depleted. When they do, tumors regain control. |
| GT Biopharma (NASDAQ: GTBP) is building its platform around amplifying these cells. |
| Its TriKE® platform is designed to keep NK cells active longer - fueling them to stay locked onto cancer cells. |
| In side-by-side comparisons, the effect was clear: |
| NK cells alone slowed tumors. But when combined with the company's TriKE® technology, cancer cells declined sharply. |
| Early human data showed up to a 63.7% reduction in cancer burden. |
| Now the company's next-generation version, showing potential for 10-40× greater potency, has cleared an important FDA milestone. |
Watch the microscopic footage and learn more
about GT Biopharma's next catalyst. |
| Market Tactic |